Vaccine News and Research

Latest Vaccine News and Research

Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia

Inviragen, a company developing vaccines to protect against infectious diseases worldwide, and the Program for the Study and Control of Tropical Diseases (PECET), jointly announced the initiation of a Phase 1 clinical trial of DENVax™ in Colombia. DENVax is an investigational vaccine designed to provide protection against all four dengue virus serotypes. The trial will measure the safety of DENVax as well as the immune responses induced by the vaccine in healthy adults in Rionegro, Colombia.

25 Oct 2010

H1N1 linked to increased rate of empyema in children

The H1N1 influenza pandemic has led to a sharp increase in the number of children with a serious "secondary" bacterial infection called empyema in children, suggests a study in the October issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

25 Oct 2010

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Immune Network Ltd. advises that a clinical trial of V5 Immunitor oral vaccine was published earlier this month demonstrating an unexpected powerful effect against tuberculosis, including multi-drug-resistant tuberculosis (MDR-TB) and tuberculosis that is complicated by co-infection with HIV and hepatitis C (HCV).

25 Oct 2010

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Soligenix, Inc. a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

25 Oct 2010

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Antigenics, Inc. today announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage® vaccine; vitespen), Antigenics' personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.

25 Oct 2010

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the five manufacturers to supply seasonal influenza vaccine to the citizens of Beijing.

25 Oct 2010

Research finds succimer drug not effective in removing mercury

Succimer, a drug used for treating lead poisoning, does not effectively remove mercury from the body, according to research supported by the National Institutes of Health. Some families have turned to succimer as an alternative therapy for treating autism.

25 Oct 2010

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Inovio Pharmaceuticals, Inc. a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a peer-reviewed research article describing the development of a new intradermal, minimally-invasive DNA vaccine delivery device was published in the prestigious journal Gene Therapy.

25 Oct 2010

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

25 Oct 2010

State Watch: N.Y. approves rate hikes; Arizona referendum on health insurance mandate; Md. insurer cuts broker fees

The Sacramento Bee: "A Sacramento federal judge has ordered the state to keep providing adult dental, podiatric and chiropractic services to poor people in underserved rural areas until it gets permission from federal health authorities to discontinue the benefits. U.S. District Judge Frank C. Damrell Jr. ruled Wednesday that, while the services are not mandatory under the federal Medicaid program (Medi-Cal in California), the Legislature's decision to end them last year as a cost-saving measure was unlawful without federal approval.

25 Oct 2010

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that Sinovac Biotech (Hong Kong) Ltd., its wholly owned subsidiary company in Hong Kong, has received the Certificate of Drug/Product Registration from the Hong Kong Department of Health for its seasonal influenza vaccine Anflu.

25 Oct 2010

Maven Semantic updates Antiviral research database

Maven Semantic announces updates to their Antiviral research database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

25 Oct 2010

Scientists use Affymetrix custom microarray to advance malarial study

Affymetrix, Inc. announced today that an international team of researchers led by scientists at Boston College, the Broad Institute, and Imperial College London used an Affymetrix custom microarray to advance the study of malaria by assessing the variation in genetic structure and detecting known and novel genetic differences among malaria vector mosquito populations.

25 Oct 2010

Paragon Bioservices awarded contract to assist USAMRIID in vaccine development efforts

Paragon Bioservices, a Baltimore-based CMO focused on the contract research, process development and manufacturing of biologics, announced today that it has been awarded a $4.99 million contract to assist the U.S. Army Medical Research Institute for Infectious Diseases in its vaccine development efforts.

22 Oct 2010

Indian, S. African leaders call for developing countries to work together, invest more in science

India's Prime Minister Manmohan Singh on Tuesday during the launch of the Third World Academy of Sciences meeting (TWAS) in Hyderabad, India, called for developing countries to place greater emphasis on scientific research and application, the Economic Times reports.

22 Oct 2010

NIH awards three new SBIR grants to Taiga

Taiga Biotechnologies, Inc. today announced that the company has received three new Small Business Innovation Research (SBIR) grants from the National Institutes of Health, totaling $1.7 million. This adds to the two previous grants awarded to Taiga for various applications of its proprietary technology platforms, for a total in NIH funding to date of over $2.1 million.

22 Oct 2010

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Idera Pharmaceuticals, Inc. today announced results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases.

22 Oct 2010

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, completes recruitment of the first group of patients in its US cervical dysplasia (CIN) phase II study of ADXS11-001 as required for the planned DMSB (safety board) meeting scheduled to be held January 11, 2011.

22 Oct 2010

Oral cancer linked to oral sex: Study

Swedish researchers have found that the Human papillomavirus (HPV) that causes cervical cancer in women is also a risk factor for oropharyngeal squamous cell carcinoma (OSCC) or oral and throat cancer in men even if they do not smoke or consume alcohol.

21 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

Vaccine News and Research

Latest Vaccine News and Research

Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia

H1N1 linked to increased rate of empyema in children

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Research finds succimer drug not effective in removing mercury

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

State Watch: N.Y. approves rate hikes; Arizona referendum on health insurance mandate; Md. insurer cuts broker fees

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Maven Semantic updates Antiviral research database

Scientists use Affymetrix custom microarray to advance malarial study

Paragon Bioservices awarded contract to assist USAMRIID in vaccine development efforts

Indian, S. African leaders call for developing countries to work together, invest more in science

NIH awards three new SBIR grants to Taiga

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Oral cancer linked to oral sex: Study

Baxter third quarter net income increases 12% to $595 million

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Vaccine News and Research

Latest Vaccine News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in